Mesoblast Limited (ASX:MSB) Featured At ASX Singapore Conference Highlighting Emerging Market Leaders

Melbourne, May 28, 2010 AEST (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.

Mesoblast was one of only two emerging market leaders in the healthcare sector that were showcased to around 150 targeted global investors. The conference featured only 15 companies, predominantly from the resources sector, with market capitalisations of up to A$1 billion.

Chief Executive, Professor Silviu Itescu, updated investors on Mesoblast's acquisition of its United States associate company, Angioblast Systems, its near term growth strategies and plans for early product revenues.

Background

Mesoblast Limited is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).

Contact

Julie Meldrum Corporate Communications Director Mesoblast Limited Tel: +61-3-9639-6036 Mob: +61-419-228-128 Email: julie.meldrum@mesoblast.com www.mesoblast.com